¼¼°èÀÇ »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀå
Biodegradable Stents
»óǰÄÚµå : 1655502
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 196 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀåÀº 2030³â±îÁö 272¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 45¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 35.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 272¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °ü»óµ¿¸Æ ½ºÅÙÆ®´Â CAGR 34.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 156¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸»Ãʵ¿¸Æ ½ºÅÙÆ®ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 35.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 11¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 42.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 85¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 42.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 26.8%¿Í 30.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 28.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ýºÐÇØ¼º ½ºÅÙÆ®°¡ ½ÉÇ÷°ü Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿Ã ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

»ýüÈí¼ö¼º ½ºÅÙÆ®¶ó°íµµ ºÒ¸®´Â »ýºÐÇØ¼º ½ºÅÙÆ®´Â µ¿¸ÆÀ» ÀϽÃÀûÀ¸·Î ÁöÁöÇÒ ¼ö ÀÖ´Â ¹ßÆÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÉÇ÷°ü Ä¡·áÀÇ ÆÇµµ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ü³»¿¡ ¿µ±¸ÀûÀ¸·Î ³²¾ÆÀÖ´Â ±âÁ¸ ±Ý¼Ó ½ºÅÙÆ®¿Í ´Þ¸® »ýºÐÇØ¼º ½ºÅÙÆ®´Â ½Ã°£ÀÌ Áö³ª¸é ³ì¾Æ ¾ø¾îÁö±â ¶§¹®¿¡ ½ºÅÙÆ®³» ÀçÇùÂøÀ̳ª Ç÷ÀüÁõ°ú °°Àº Àå±âÀûÀÎ ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü°è ÁúȯÀÌ Àü ¼¼°è¿¡¼­ ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ´Â »óȲ¿¡¼­ Ç÷·ù¸¦ ȸº¹½Ãų »Ó¸¸ ¾Æ´Ï¶ó ü³»¿¡¼­ ¾ÈÀüÇÏ°Ô ºÐÇØµÇ´Â ½ºÅÙÆ®ÀÇ °³¹ßÀº ÀÇ·á ±â¼úÀÇ Å« ¹ßÀüÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº Àå±âÀûÀÎ ºÎÀÛ¿ëÀÌ ÀûÀº ÃÖ¼Òħ½ÀÀû Ä¡·á¸¦ ÇÊ¿ä·Î Çϴ ȯÀڵ鿡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

»ýºÐÇØ¼º ½ºÅÙÆ® ¼ÒÀçÀÇ Ãֽбâ¼ú Çõ½ÅÀ̶õ?

»ýºÐÇØ¼º ½ºÅÙÆ®¿ë ½Å¼ÒÀç °³¹ßÀº ÀÇ·á±â±â Á¦Á¶¾÷üµé¿¡°Ô Áß¿äÇÑ ºÐ¾ßÀÔ´Ï´Ù. Ãʱ⠻ýºÐÇØ¼º ½ºÅÙÆ®´Â Æú¸®À¯»ê(PLA)°ú °°Àº Àç·á·Î ¸¸µé¾îÁ³Áö¸¸, º¸´Ù Áøº¸µÈ Æú¸®¸Ó¿Í ¸¶±×³×½· ±â¹Ý Çձݰú °°Àº ±Ý¼Ó È­ÇÕ¹°¿¡ ´ëÇÑ ¿¬±¸´Â ¼º´É Çâ»óÀ» À§ÇÑ »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ¼ÒÀç´Â ´õ ³ªÀº ±â°èÀû °­µµ, À¯¿¬¼º, Á¦¾îµÈ ºÐÇØ ¼Óµµ¸¦ Á¦°øÇÏ¿© °³º° ȯÀÚÀÇ ¿ä±¸¿¡ ¸Â´Â ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ Ç¥¸é ÄÚÆÃÀÇ ¹ßÀüÀ¸·Î »ýü ÀûÇÕ¼ºÀÌ Çâ»óµÇ°í ¿°ÁõÀÌ ¾ïÁ¦µÇ¾î ½ÉÇ÷°ü°èÀÇ Àå±âÀûÀÎ ÇコÄɾ ´õ¿í È¿°úÀûÀÎ ½ºÅÙÆ®¸¦ ¸¸µé ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

»ýºÐÇØ¼º ½ºÅÙÆ®´Â ½ÉÀ庴ÇÐ ÀÌ¿ÜÀÇ ´Ù¸¥ ºÐ¾ß·Î ¾î¶»°Ô È®»êµÇ°í Àִ°¡?

»ýºÐÇØ¼º ½ºÅÙÆ®´Â ¿ø·¡ ½ÉÀåÇпëÀ¸·Î °³¹ßµÇ¾úÁö¸¸, ¼ÒÈ­±â, ºñ´¢±â, Á¤Çü¿Ü°ú µî ´Ù¸¥ ÀÇ·á ºÐ¾ß·Î ±× ¿ëµµ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼ÒÈ­±â ¿Ü°ú¿¡¼­ »ýºÐÇØ¼º ½ºÅÙÆ®´Â ½Äµµ ÇùÂø µîÀÇ Ä¡·á¿¡ »ç¿ëµÇ¸ç, ºñ´¢±â°ú¿¡¼­´Â ¿ä·Î¸¦ ÀϽÃÀûÀ¸·Î ÁöÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ÀÇ·á ºÐ¾ß·ÎÀÇ È®ÀåÀº »ýºÐÇØ¼º ½ºÅÙÆ® ±â¼úÀÇ ¹ü¿ë¼ºÀ» °­Á¶Çϸç, ´Ù¾çÇÑ Àü¹® ºÐ¾ßÀÇ ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ºÅÙÆ®°¡ ¸ñÀûÀ» ´Þ¼ºÇÑ ÈÄ ¿ëÇØµÇ´Â ´É·ÂÀº ÀϽÃÀûÀÎ ÁöÁö´ë°¡ ÇÊ¿äÇÏÁö¸¸ ¿µ±¸ÀûÀÎ ÀÓÇöõÆ®¸¦ ¿øÇÏÁö ¾Ê´Â ȯÀڵ鿡°Ô ȹ±âÀûÀÎ ±â¼úÀÔ´Ï´Ù.

»ýºÐÇØ¼º ½ºÅÙÆ® º¸±ÞÀÇ °úÁ¦´Â?

»ýºÐÇØ¼º ½ºÅÙÆ®ÀÇ ÀåÁ¡¿¡µµ ºÒ±¸ÇÏ°í »ýºÐÇØ¼º ½ºÅÙÆ®´Â ±× º¸±ÞÀ» Á¦ÇÑÇÒ ¼ö ÀÖ´Â ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä °ü½É»ç Áß Çϳª´Â ±âÁ¸ ½ºÅÙÆ®¿¡ ´ëÇÑ È¿°ú¸¦ ÀÔÁõÇϱâ À§ÇØ Àå±âÀûÀÎ ÀÓ»ó µ¥ÀÌÅͰ¡ ÇÊ¿äÇÏ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ ±â¼úÀº ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °ÍÀ¸·Î º¸ÀÌÁö¸¸, ÀϺΠÀÇ·áÁøÀº ±â°èÀû ¹«°á¼º ¹× Á¶±â ¿­È­¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ¿©ÀüÈ÷ ÁÖÀúÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±âÁ¸ ½ºÅÙÆ®¿¡ ºñÇØ »ýºÐÇØ¼º ½ºÅÙÆ®°¡ ºñ½Î´Ù´Â Á¡Àº ºñ¿ë¿¡ ¹Î°¨ÇÑ ÀÇ·á ½ÃÀå¿¡¼­ À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀÇ ÀáÀç·ÂÀ» ±Ø´ëÈ­Çϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ ¿¬±¸°³¹ßÀ» ÅëÇØ ÀÌ·¯ÇÑ ¿ì·Á¸¦ ÇØ°áÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. »ýºÐÇØ¼º ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, »ýü Àç·á ±â¼úÀÇ ¹ßÀü, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ȯÀÚµéÀÇ ¼±È£µµ°¡ À̹°ÁúÀÇ Ã¼·ù¸¦ ÃÖ¼ÒÈ­ÇÏ´Â Ä¡·á¹ýÀ¸·Î ¿Å°Ü°¡°í ÀÖ´Â °¡¿îµ¥, »ýºÐÇØ¼º ½ºÅÙÆ®´Â À¯¸ÁÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀåºñÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇÏ´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÀÓ»ó½ÃÇèµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýºÐÇØ¼º ½ºÅÙÆ®ÀÇ ºñ½ÉÀå ºÐ¾ß¿¡¼­ÀÇ »ç¿ë È®´ë¿Í ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡´Â ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃŰ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÃÖÁ¾ ¿ëµµ(º´¿ø, ½ÉÀå¼¾ÅÍ);&¼ÒÀç À¯Çü(Æú¸®¸Ó ±â¹Ý, ±Ý¼Ó ±â¹Ý);&½ºÅÙÆ® À¯Çü(°ü»óµ¿¸Æ ½ºÅÙÆ®, ¸»Ãʵ¿¸Æ ½ºÅÙÆ®)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 46»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Biodegradable Stents Market to Reach US$27.2 Billion by 2030

The global market for Biodegradable Stents estimated at US$4.5 Billion in the year 2024, is expected to reach US$27.2 Billion by 2030, growing at a CAGR of 35.0% over the analysis period 2024-2030. Coronary Artery Stents, one of the segments analyzed in the report, is expected to record a 34.9% CAGR and reach US$15.6 Billion by the end of the analysis period. Growth in the Peripheral Artery Stents segment is estimated at 35.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 42.8% CAGR

The Biodegradable Stents market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.5 Billion by the year 2030 trailing a CAGR of 42.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 26.8% and 30.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 28.8% CAGR.

Global Biodegradable Stents Market - Key Trends & Drivers Summarized

Why Are Biodegradable Stents Revolutionizing Cardiovascular Care?

Biodegradable stents, also known as bioresorbable stents, are transforming the landscape of cardiovascular treatment by offering a temporary scaffold for arterial support. Unlike traditional metal stents, which remain in the body indefinitely, biodegradable stents dissolve over time, reducing the risk of long-term complications such as in-stent restenosis and thrombosis. As cardiovascular diseases continue to be a leading cause of morbidity and mortality globally, the development of stents that not only restore blood flow but also degrade safely within the body is a major advancement in medical technology. This innovation is crucial for patients requiring minimally invasive treatments with reduced long-term side effects.

What Are the Latest Innovations in Biodegradable Stent Materials?

The development of new materials for biodegradable stents is a major area of focus for medical device manufacturers. Early biodegradable stents were made from materials like polylactic acid (PLA), but research into more advanced polymers and metallic compounds, such as magnesium-based alloys, has opened new possibilities for improved performance. These newer materials offer better mechanical strength, flexibility, and controlled degradation rates, allowing for more tailored solutions to individual patient needs. Moreover, advances in surface coatings are helping to enhance biocompatibility and reduce inflammation, making these stents more effective in the long-term management of cardiovascular health.

How Are Biodegradable Stents Expanding Beyond Cardiology?

While biodegradable stents were initially developed for cardiology applications, their use is expanding into other areas of medicine, such as gastroenterology, urology, and orthopedics. In gastrointestinal procedures, biodegradable stents are used to treat conditions like esophageal strictures, while in urology, they can provide temporary support in the urinary tract. This expansion into new medical fields underscores the versatility of biodegradable stent technology, making it an essential tool in minimally invasive procedures across a broad range of specialties. The ability of these stents to dissolve after serving their purpose is a game-changer for patients who require temporary scaffolding but do not want permanent implants.

What Are the Challenges in Widespread Adoption of Biodegradable Stents?

Despite their advantages, biodegradable stents face several challenges that could limit their widespread adoption. One of the primary concerns is the need for longer-term clinical data to prove their efficacy over traditional stents. While the technology has shown promise in clinical trials, there is still hesitation among some medical professionals due to concerns over mechanical integrity and premature degradation. Furthermore, the high cost of biodegradable stents compared to conventional stents can be a barrier in cost-sensitive healthcare markets. Addressing these concerns through continued research and development is essential to unlock the full potential of this innovative technology. The growth in the biodegradable stents market is driven by several factors, including the increasing prevalence of cardiovascular diseases, advancements in biomaterial technologies, and the growing demand for minimally invasive procedures. As patient preferences shift toward treatments that minimize foreign body retention, biodegradable stents offer a promising solution. Regulatory approvals and clinical trials demonstrating the safety and efficacy of these devices are also propelling market growth. Additionally, the expanding use of biodegradable stents in non-cardiac applications and the rising geriatric population, who are more prone to chronic diseases, are further contributing to the increased demand for these innovative medical devices.

SCOPE OF STUDY:

The report analyzes the Biodegradable Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Hospitals, Cardiac Centers); Material Type (Polymer Based, Metal Based); Stent Type (Coronary Artery Stents, Peripheral Artery Stents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â